Cancer Chemotherapy and Pharmacology

, Volume 74, Issue 6, pp 1207–1215 | Cite as

A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy

  • Tsuyoshi Shirakawa
  • Ken Kato
  • Kengo Nagashima
  • Akiko Nishikawa
  • Ryoichi Sawada
  • Naoki Takahashi
  • Hirokazu Shoji
  • Yusuke Sasaki
  • Yoshitaka Honma
  • Satoru Iwasa
  • Atsuo Takashima
  • Natsuko Okita
  • Tetsuya Hamaguchi
  • Yasuhide Yamada
  • Yasuhiro Shimada
Original Article

Abstract

Introduction

Fluoropyrimidine plus platinum (FP)-based chemotherapy has been widely used as a first-line regimen for advanced or recurrent esophageal cancer, and taxanes have shown efficacy after FP-based chemotherapy, but there is no standard regimen for second-line chemotherapy (SLC). We retrospectively investigated the clinical features of taxane therapy in SLC for esophageal squamous cell carcinoma (ESCC).

Methods

The selection criteria were pathologically proven ESCC; advanced or recurrent disease previously treated with FP at our hospital; performance status (PS) 0–2; and adequate organ function. Docetaxel (DTX) was administered 3-weekly at 70 mg/m2. Paclitaxel (PTX) was administered at 100 mg/m2 weekly for 6 weeks, with 1 week’s rest.

Results

The analysis covered 163 patients from August 2006 to June 2012. Median age was 64 years (range 37–83: DTX group 132 patients and PTX group 31). Progression-free survival and median overall survival (OS) were 2.3 and 6.1 months, respectively, with PTX and 2.3 and 5.3 months with DTX. Response rates were 20.7 % for PTX and 5.9 % for DTX. The rate of grades 3–4 neutropenia was higher with DTX (32.6 %) than with PTX (16.1 %). Grade 3 febrile neutropenia was seen in 6.1 % of DTX recipients but in no PTX group. According to multivariate analyses of OS, PS 2, number of metastatic sites ≧2, and CRP ≧1 mg/dL were independent predictors of poor prognosis.

Conclusions

PTX and DTX were both effective in SLC for ESCC, but their toxicity profiles differed. In terms of febrile neutropenia, PTX seems more appropriate.

Keywords

Docetaxel Esophageal squamous cell carcinoma Paclitaxel Prognostic factor Second-line chemotherapy 

References

  1. 1.
    Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30PubMedCrossRefGoogle Scholar
  2. 2.
    Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90PubMedCrossRefGoogle Scholar
  3. 3.
    Demographic statistics. Ministry of Health, Labour and Welfare, Japan, 2006Google Scholar
  4. 4.
    Hayashi K, Ando N, Watanabe H et al (2001) Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) trial (JCOG9407). Jpn J Clin Oncol 31(9):419–423PubMedCrossRefGoogle Scholar
  5. 5.
    Ilson DH (2003) Oesophageal cancer: new developments in systemic therapy. Cancer Treat Rev 29:525–532PubMedCrossRefGoogle Scholar
  6. 6.
    Bleiberg H, Conroy T, Paillot B et al (1997) Randomized phase II study of cisplatin and 5-FU versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 33:1216–1220PubMedCrossRefGoogle Scholar
  7. 7.
    Vanhoefer U, Rougier P, Wilke H et al (2000) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 18:2648–2657PubMedGoogle Scholar
  8. 8.
    Muro K, Hamaguchi T, Ohtsu A et al (2004) A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 15(6):955–959PubMedCrossRefGoogle Scholar
  9. 9.
    Kato K, Tahara M, Hironaka S et al (2011) A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol 67(6):1265–1272PubMedCrossRefGoogle Scholar
  10. 10.
    Heath EI, Urba S, Marshall J et al (2002) Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Investig New Drugs 20(1):95–99CrossRefGoogle Scholar
  11. 11.
    Anderson SE, O’Reilly EM, Kelsen DP et al (2003) Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer. Cancer Invest 21:512–516PubMedCrossRefGoogle Scholar
  12. 12.
    Thallinger CMR, Raderer M, Hejna M (2011) Esophageal cancer: a critical evaluation of systemic second-line therapy. J Clin Oncol 29(35):4709–4714PubMedCrossRefGoogle Scholar
  13. 13.
    Hirao M, Ando N, Tsujinaka T et al (2011) Influence of preoperative chemotherapy for advanced thoracic oesophageal squamous cell carcinoma on perioperative complications. Br J Surg 98(12):1735–1741PubMedCrossRefGoogle Scholar
  14. 14.
    Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349:2241–2252PubMedCrossRefGoogle Scholar
  15. 15.
    Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRefGoogle Scholar
  16. 16.
    Cox DR (1972) Regression models and life-tables. J R Stat Soc B 34:187–202Google Scholar
  17. 17.
    Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17(4):343–346PubMedCrossRefGoogle Scholar
  18. 18.
    Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRefGoogle Scholar
  19. 19.
    Peto R, Peto J (1972) Asymptotically efficient rank invariant test procedures. J R Stat Soc A 135(2):185–207CrossRefGoogle Scholar
  20. 20.
    Lorenzen S, Schuster T, Porschen R et al (2009) Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 20(10):1667–1673PubMedCrossRefGoogle Scholar
  21. 21.
    Mizota A, Shitara K, Kondo C et al (2011) A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy. Oncology 81(3–4):237–242PubMedCrossRefGoogle Scholar
  22. 22.
    Smith EM, Pang H, Cirrincione C et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309(13):1359–1367PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Takenaka M, Iida H, Matsumoto S et al (2013) Successful treatment by adding duloxetine to pregabalin for peripheral neuropathy induced by paclitaxel. Am J Hosp Palliat Care 30(7):734–736PubMedCrossRefGoogle Scholar
  24. 24.
    Caraceni A, Zecca E, Bonezzi C et al (2004) Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 22(14):2909–2917PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Tsuyoshi Shirakawa
    • 1
    • 2
  • Ken Kato
    • 1
  • Kengo Nagashima
    • 3
  • Akiko Nishikawa
    • 1
  • Ryoichi Sawada
    • 1
  • Naoki Takahashi
    • 1
  • Hirokazu Shoji
    • 1
  • Yusuke Sasaki
    • 1
  • Yoshitaka Honma
    • 1
  • Satoru Iwasa
    • 1
  • Atsuo Takashima
    • 1
  • Natsuko Okita
    • 1
  • Tetsuya Hamaguchi
    • 1
  • Yasuhide Yamada
    • 1
  • Yasuhiro Shimada
    • 1
  1. 1.Gastrointestinal Medical Oncology DivisionNational Cancer Center HospitalTokyoJapan
  2. 2.Department of Gastrointestinal and Medical OncologyNational Hospital Organization Kyushu Cancer CenterFukuoka-shiJapan
  3. 3.Clinical Research CenterChiba University HospitalChibaJapan

Personalised recommendations